Research Analysts Offer Predictions for INTS FY2026 Earnings

Intensity Therapeutics Inc. (NASDAQ:INTS) – Analysts at Brookline Capital Markets dropped their FY2026 earnings per share estimates for Intensity Therapeutics in a report released on Thursday, November 5th. Brookline Capital Markets analyst K. Raja now anticipates that the company will post earnings per share of ($4.15) for the year, down from their prior estimate of ($3.41). The consensus estimate for Intensity Therapeutics’ current full-year earnings is ($2.64) per share. Brookline Capital Markets also issued estimates for Intensity Therapeutics’ Q4 2026 earnings at ($0.99) EPS, FY2027 earnings at ($3.06) EPS, FY2028 earnings at ($7.32) EPS, FY2029 earnings at $8.09 EPS and FY2030 earnings at $14.82 EPS.

INTS has been the subject of a number of other research reports. Citigroup reissued a “buy” rating on shares of Intensity Therapeutics in a report on Tuesday, August 11th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Intensity Therapeutics in a report on Monday, October 19th. Finally, HC Wainwright lifted their price target on shares of Intensity Therapeutics from $5.00 to $7.00 and gave the company a “buy” rating in a research report on Tuesday, August 18th. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $7.00.

Intensity Therapeutics Price Performance

NASDAQ:INTS opened at $3.15 on Tuesday. Intensity Therapeutics has a 52 week low of $2.80 and a 52 week high of $15.00. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.00 and a current ratio of 5.00. The firm’s 50-day simple moving average is $3.61 and its 200 day simple moving average is $5.07. The firm has a market cap of $10.27 million, a price-to-earnings ratio of -0.88 and a beta of 2.78.

Intensity Therapeutics (NASDAQ:INTS) last released its quarterly earnings results on Thursday, November 5th. The company reported ($1.09) EPS for the quarter, missing the consensus estimate of ($0.99) by ($0.10).

Key Stories Impacting Intensity Therapeutics

Here are the key news stories impacting Intensity Therapeutics this week:

• Positive Sentiment: HC Wainwright reiterated its Buy rating and $7.00 price target, signaling continued analyst support despite its lower earnings forecasts. MarketBeat coverage
• Positive Sentiment: Brookline raised its projected EPS for 2029 to $8.09 from $7.40 and for 2030 to $14.82 from $13.27, suggesting improved expectations for those out-years. MarketBeat coverage
• Negative Sentiment: Both firms cut near-term earnings expectations. HC Wainwright lowered its 2026 EPS forecast to a loss of $4.48 from $1.88 and its 2027 forecast to a loss of $1.67 from $0.92. Brookline also reduced its 2026 and 2027 estimates, to losses of $4.15 and $3.06, respectively. Larger expected losses may pressure the shares. MarketBeat coverage
• Negative Sentiment: Brookline also widened its projected 2028 loss, to $7.32 per share from $6.01, tempering the more optimistic revisions it made for 2029 and 2030. MarketBeat coverage

About Intensity Therapeutics

Intensity Therapeutics, Inc (NASDAQ: INTS) is a clinical-stage biotechnology company developing investigational cancer immunotherapies designed to treat solid tumors. Its approach focuses on injecting therapies directly into tumors to promote tumor-cell destruction and stimulate a broader immune response against cancer.

The company’s lead product candidate, INT230-6, is a proprietary formulation containing the chemotherapy agents cisplatin and vinblastine combined with an amphiphilic delivery agent.